Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies

Journal of the Royal Statistical Society. Series A: Statistics in Society

Volumn 177, Issue 2, 2014, Pages 419-438

  Pertile, Paolo ^a   Forster, Martin ^b   Torre, Davide La ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Bayesian; Dynamic programming; Economic evaluation; Sequential sampling

Indexed keywords

EID: 84893764894     PISSN: 09641998     EISSN: 1467985X     Source Type: Journal    
DOI: 10.1111/rssa.12025     Document Type: Article

References (57)

1. Anscombe, F. J. (1963) Sequential medical trials. J. Am. Statist. Ass., 58, 365-383.
2. Armitage, P., McPherson, C. K. and Rowe, B. C. (1969) Repeated significance tests on accumulating data. J. R. Statist. Soc. A, 132, 235-244.
3. Attema, A. E., Lugnér, A. K. and Feenstra, T. L. (2010) Investment in antiviral drugs: a real options approach. Hlth Econ., 19, 1240-1254.
4. Barton, G. R., Briggs, A. H. and Fenwick, E. A. (2008) Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Val. Hlth, 11, 886-897.
5. Bellman, R. E. (1957) Dynamic Programming, 1st edn. Princeton: Princeton University Press.
6. Bellman, R. E. and Dreyfus, S. (1962) Applied Dynamic Programming, 1st edn. Princeton: Princeton University Press.
7. Berry, D. A. (1985) Interim analyses in clinical trials: classical vs. Bayesian approaches. Statist. Med., 4, 521-526.
8. Berry, D. A. and Ho, C. (1988) One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. Biometrics, 44, 219-227.
9. Brezzi, M. and Lai, T. L. (2002) Optimal learning and experimentation in bandit problems. J. Econ. Dynam. Control, 27, 87-108.
10. Burman, C. and Senn, S. (2003) Examples of option values in drug development. Pharm. Statist., 2, 113-125.
11. Carlin, B. P., Kaldane, J. B. and Gelfand, A. E. (1998) Approaches for optimal sequential decision analysis in clinical trials. Biometrics, 54, 964-975.
12. Chernoff, H. (1961) Sequential tests for the mean of a normal distribution. In Proc. 4th Berkeley Symp. Mathematical Statistics and Probability, vol. J. Neyman), pp. 79-91. Berkeley: University of California Press.
13. Chernoff, H. (1965a) Sequential tests for the mean of a normal distribution III. Ann. Math. Statist., 36, 28-54.
14. Chernoff, H. (1965b) Sequential tests for the mean of a normal distribution IV. Ann. Math. Statist., 36, 55-68.
15. Chernoff, H. and Petkau, A. J. (1981) Sequential medical trials involving paired data. Biometrika, 68, 119-132.
16. Chick, S. E. and Frazier, P. (2012) Sequential sampling with economics of selection procedures. Mangmnt Sci., 58, 550-569.
17. Chick, S. E. and Gans, N. (2009) Economic analysis of simulation selection problems. Mangmnt Sci., 55, 421-437.
18. Claxton, K. (1999) The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J. Hlth Econ., 18, 341-364.
19. Claxton, K., Fenwick, E. and Sculpher, M. J. (2012) Decision-making with uncertainty: the value of information. In The Elgar Companion to Health Economics (ed. A. Jones), 2nd edn, ch. 51, pp. 550-561. Cheltenham: Elgar.
20. Claxton, K. and Thompson, K. (2001) A dynamic programming approach to efficient clinical trial design. J. Hlth Econ., 20, 797-822.
21. Colton, T. (1963) A model for selecting one of two medical treatments. J. Am. Statist. Ass., 58, 388-400.
22. Conti, S. and Claxton, K. (2009) Dimensions of design space: a decision-theoretic approach to optimal research design. Med. Decsn Makng, 29, 643-660.
23. DeGroot, M. H. (1970) Optimal Statistical Decisions, 1st edn. New York: McGraw-Hill.
24. Detsky, A. S. (1990) Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials. Statist. Med., 9, 173-184.
25. Dixit, A. and author"Pindyck, R. (1994) Investment under Uncertainty, 1st edn. Princeton: Princeton University Press.
26. Emerson, S. S., Kittelson, J. M. and Gillen, D. L. (2007a) Bayesian evaluation of group sequential clinical trial designs. Statist. Med., 26, 1431-1449.
27. Emerson, S. S., Kittelson, J. M. and Gillen, D. L. (2007b) Frequentist evaluation of group sequential clinical trial designs. Statist. Med., 26, 5047-5080.
28. Ghosh, B. K. (1991) A brief history of sequential analysis. In Handbook of Sequential Analysis (eds B. K. Ghosh and P. K. Sen), 1st edn, ch. 1, pp. 1-19. New York: Dekker.
29. Griffin, S., Welton, N. J. and Claxton, K. (2010) Exploring the research decision space: the expected value of information for sequential research designs. Med. Decsn Makng, 30, 155-162.
30. Hoyle, M. (2010) Historical lifetimes of drugs in England: application to value of information and cost-effectiveness analysis. Val. Hlth, 13, 885-892.
31. Hsiao, C. F. and Clayton, M. K. (2007) Bayes optimal sequential trial designs. J. Statist. Planng Inf., 137, 1129-1137.
32. Jennison, C. and Turnbull, B. W. (2000) Group Sequential Methods with Applications to Clinical Trials, 1st edn. New York: Chapman and Hall.
33. Lai, T. L., Levin, B., Robbins, H. and Siegmund, D. (1980) Sequential medical trials. Proc. Natn. Acad. Sci. USA, 77, 3135-3138.
34. Lai, T. and Lim, T. (2005) Optimal stopping for brownian motion with applications to sequential analysis and option pricing. J. Statist. Planng Inf., 130, 21-47.
35. Lewis, R. J. and Berry, D. A. (1994) Group sequential clinical trials: a classical evaluation of Bayesian decision-theoretic designs. J. Am. Statist. Ass., 89, 1528-1534.
36. Lewis, R. J., Lipsky, A. M. and Berry, D. A. (2007) Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation. Clin. Trials, 4, 5-14.
37. Marple, B. F., Roberts, C. S., Frytak, J. R., Schabert, V. F., Wegner, J. C., Bhattacharayya, H., Piccirillo, J. F. and Sanchez, S. P. (2010) Azithromycin extended release vs. amoxicillin/clavulanate: symptom resolution in acute sinusitis. Am. J. Otolaryng., 31, 1-8.
38. Matlab (2012) Matlab 7.14.0.739 (R2012a). Natick: Mathworks.
39. McKenna, C., Chalabi, Z., Epstein, D. and Claxton, K. (2010) Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. J. Hlth Econ., 29, 170-181.
40. Meltzer, D. O., Hoomans, T., Chung, J. W. and Basu, A. (2011) Minimal modelling approaches to value of information analysis for health research. Med. Decsn Makng, 31, E1-E22.
41. Meltzer, D. O. and Smith, P. C. (2012) Theoretical issues relevant to the economic evaluation of health technologies. In Handbook of Health Economics, vol. (eds M. V. Pauly, T. G. McGuire and P. P. Baros). Oxford: Elsevier.
42. National Institute for Health and Clinical Excellence (2008) Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence.
43. O'Brien, P. C. and Fleming, T. R. (1979) A multiple testing procedure for clinical trials. Biometrics, 35, 549-556.
44. Palmer, S. and Smith, P. C. (2000) Incorporating option values into the economic evaluation of health care technologies. J. Hlth Econ., 19, 755-766.
45. Pertile, P. (2009) An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography. Int. J. Hlth Care Finan. Econ., 9, 317-332.
46. Pratt, J., Raiffa, H. and Schlaifer, R. (1995) Introduction to Statistical Decision Theory, 2nd edn. Cambridge: MIT Press.
47. Roberts, K. and Weitzman, M. L. (1981) Funding criteria for research, development and exploration projects. Econometrica, 49, 1261-1288.
48. Thomson Healthcare (2010) Drug Topics Red Book. Montvale: Thomson Reuters.
49. Tolley, G., Babcock, L., Berger, M., Bilotti, A., Blomquist, G., Brien, M., Fabian, R., Fishelson, G., Kahn, C., Kelly, A., Kenkel, D., Krumm, R., Miller, T., Ohsfeldt, R., Rosen, S., Webb, W., Wilson, W. and Lelder, M. (1986) Valuation of reductions in human health symptoms and risk. Final Report. University of Chicago, Chicago.
50. Wald, A. (1947) Foundations of a general theory of sequential decision functions. Econometrica, 15, 279-313.
51. Wald, A. and Wolfowitz, J. (1948) Optimal character of the sequential probability ratio test. Ann. Math. Statist., 19, 326-339.
52. Welton, N. and Ades, A. E. (2012) Research decisions in the face of heterogeneity: what can a new study tell us? Hlth Econ., 21, 1196-1200.
53. Whitehead, J. (1997) The Design and Analysis of Sequential Clinical Trials, 2nd edn. Chichester: Wiley.
54. Willan, A. R. and Eckermann, S. (2010) Optimal clinical trial design using value of information methods with imperfect implementation. Hlth Econ., 19, 549-561.
55. Willan, A. R. and Eckermann, S. (2012) Accounting for between-study variation in incremental net benefit in value of information methodology. Hlth Econ., 21, 1183-1195.
56. Willan, A. and Kowgier, M. (2008) Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Clin. Trials, 5, 289-300.
57. Wilmott, P., Howison, S. and Dewynne, J. (1993) The Mathematics of Financial Derivatives, 1st edn. Cambridge: Cambridge University Press.